Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine hydrochloride monohydrate implant - Foundry Therapeutics 1

Next Previous
Drug Profile

Bupivacaine hydrochloride monohydrate implant - Foundry Therapeutics 1

Alternative Names: Bupivacaine HCl releasing bioresorbable implant system - Foundry Therapeutics 1; Bupivacaine implant - Foundry Therapeutics 1; TKAine; TKAine depot; Tkaine system

Latest Information Update: 19 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foundry Therapeutics 1
  • Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Postoperative pain

Most Recent Events

  • 27 Feb 2020 Phase-I/II clinical trials in Postoperative pain in Australia (Implant) (ACTRN12619000775112)
  • 29 May 2019 Foundry Therapeutics 1 plans a phase I/II trial for Post operative pain in, patients following total knee arthroplasty procedures, in Australia (ACTRN12619000775112p)
  • 29 May 2019 Preclinical trials in Postoperative pain in Australia (Implant) before May 2019 (ACTRN12619000775112p)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top